Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Biochimica Et Biophysica Acta|September 3, 2014
FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1Angel L Pey, Clare F Megarity, David J Timson
Bioscience Reports|December 7, 2018
NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right placesAngel L Pey, Clare F Megarity, David J Timson
International Journal of Biological Macromolecules|November 27, 2024
The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding diseaseAtanasio Gómez-Mulas, Athi N Naganathan, Angel L Pey
Antioxidants (Basel, Switzerland)|August 23, 2020
The Catalytic Cycle of the Antioxidant and Cancer-Associated Human NQO1 Enzyme: Hydride Transfer, Conformational Dynamics and Functional CooperativityErnesto Anoz-Carbonell, David J Timson, Angel L Pey, et al.
FEBS Letters|August 4, 2017
A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80RInés G Muñoz, Bertrand Morel, Encarnación Medina-Carmona, et al.
Handbook of Experimental Pharmacology|October 11, 2017
Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in CancerIsabel Betancor-Fernández, David J Timson, Eduardo Salido, et al.
Journal of Personalized Medicine|February 10, 2021
Galactosemia: Towards Pharmacological ChaperonesSamantha Banford, Thomas J McCorvie, Angel L Pey, et al.
Biochemistry|January 23, 2013
Structural and energetic basis of protein kinetic destabilization in human phosphoglycerate kinase 1 deficiencyAngel L Pey, Noel Mesa-Torres, Laurent R Chiarelli, et al.
Biochemical Society Transactions|February 11, 2016
Galactokinase promiscuity: a question of flexibility?Megan McAuley, Helena Kristiansson, Meilan Huang, et al.
Archives of Biochemistry and Biophysics|August 24, 2014
The metastability of human UDP-galactose 4'-epimerase (GALE) is increased by variants associated with type III galactosemia but decreased by substrate and cofactor bindingAngel L Pey, Esperanza Padín-Gonzalez, Noel Mesa-Torres, et al.
Pageof 10